Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 172

    1.

    Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.

    SMART Study Group, El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ, Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton JD.

    Ann Intern Med. 2008 Sep 2;149(5):289-99.PMID: 18765698 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    CD4+ count-guided interruption of antiretroviral treatment.

    Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, Babiker A, Burman W, Clumeck N, Cohen CJ, Cohn D, Cooper D, Darbyshire J, Emery S, Fätkenheuer G, Gazzard B, Grund B, Hoy J, Klingman K, Losso M, Markowitz N, Neuhaus J, Phillips A, Rappoport C.

    N Engl J Med. 2006 Nov 30;355(22):2283-96.PMID: 17135583 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.

    García F, Romeu J, Grau I, Sambeat MA, Dalmau D, Knobel H, Gomez-Sirvent JL, Arrizabalaga J, Cruceta A, Clotet BG, Podzamczer D, Pumarola T, Gallart T, O'Brien WA, Miró JM, Gatell JM.

    AIDS. 1999 Dec 3;13(17):2377-88.PMID: 10597779 [PubMed - indexed for MEDLINE]Related articles

    4.

    AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

    Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

    JAMA. 1999 Dec 15;282(23):2220-6.PMID: 10605973 [PubMed - indexed for MEDLINE]Related articlesFree article

    5.

    Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.

    Currier JS, Williams PL, Koletar SL, Cohn SE, Murphy RL, Heald AE, Hafner R, Bassily EL, Lederman HM, Knirsch C, Benson CA, Valdez H, Aberg JA, McCutchan JA.

    Ann Intern Med. 2000 Oct 3;133(7):493-503.PMID: 11015162 [PubMed - indexed for MEDLINE]Related articlesFree article

    6.

    Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.

    Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN.

    J Infect Dis. 2008 Apr 15;197(8):1145-55.PMID: 18476293 [PubMed - indexed for MEDLINE]Related articles

    7.

    Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.

    Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.

    Ann Intern Med. 2001 Dec 4;135(11):954-64.PMID: 11730396 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.

    Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R.

    J Infect Dis. 2008 Apr 15;197(8):1133-44.PMID: 18476292 [PubMed - indexed for MEDLINE]Related articles

    9.

    Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

    Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

    JAMA. 2001 Nov 28;286(20):2568-77.PMID: 11722271 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection.

    Ormaasen V, Bruun JN, Sandvik L, Holberg-Petersen M, Gaarder PI.

    Scand J Infect Dis. 2003;35(6-7):383-8.PMID: 12953949 [PubMed - indexed for MEDLINE]Related articles

    11.

    The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy.

    Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Levine A, Young M, Gange SJ.

    Ann Intern Med. 2004 Feb 17;140(4):256-64.PMID: 14970148 [PubMed - indexed for MEDLINE]Related articlesFree article

    12.

    Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team.

    Hughes MD, Johnson VA, Hirsch MS, Bremer JW, Elbeik T, Erice A, Kuritzkes DR, Scott WA, Spector SA, Basgoz N, Fischl MA, D'Aquila RT.

    Ann Intern Med. 1997 Jun 15;126(12):929-38.PMID: 9182469 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

    Chêne G, Binquet C, Moreau JF, Neau D, Pellegrin I, Malvy D, Ceccaldi J, Lacoste D, Dabis F.

    AIDS. 1998 Dec 3;12(17):2313-20.PMID: 9863874 [PubMed - indexed for MEDLINE]Related articles

    14.

    Phase III study of granulocyte-macrophage colony-stimulating factor in advanced HIV disease: effect on infections, CD4 cell counts and HIV suppression. Leukine/HIV Study Group.

    Angel JB, High K, Rhame F, Brand D, Whitmore JB, Agosti JM, Gilbert MJ, Deresinski S.

    AIDS. 2000 Mar 10;14(4):387-95.PMID: 10770541 [PubMed - indexed for MEDLINE]Related articles

    15.

    Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy.

    Salmon-Céron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, Katlama C, Matheron S, Fillet AM, Gozlan J, Leport C, Jeantils V, Freymuth F, Costagliola D.

    AIDS. 2000 May 26;14(8):1041-9.PMID: 10853987 [PubMed - indexed for MEDLINE]Related articles

    16.

    Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial.

    Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F.

    AIDS. 2004 Feb 20;18(3):439-46.PMID: 15090796 [PubMed - indexed for MEDLINE]Related articles

    17.

    Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.

    Ruiz L, Paredes R, Gómez G, Romeu J, Domingo P, Pérez-Alvarez N, Tambussi G, Llibre JM, Martínez-Picado J, Vidal F, Fumaz CR, Clotet B; TIBET Study Group.

    AIDS. 2007 Jan 11;21(2):169-78.PMID: 17197807 [PubMed - indexed for MEDLINE]Related articles

    18.

    Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.

    Ananworanich J, Siangphoe U, Hill A, Cardiello P, Apateerapong W, Hirschel B, Mahanontharit A, Ubolyam S, Cooper D, Phanuphak P, Ruxrungtham K.

    J Acquir Immune Defic Syndr. 2005 Aug 15;39(5):523-9.PMID: 16044002 [PubMed - indexed for MEDLINE]Related articles

    19.

    HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load.

    Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, Miller V, Vernazza P, Lundgren JD, Ledergerber B; Swiss HIV Cohort Study; Frakfurt HIV Clinic Cohort; EuroSIDA Study Group.

    JAMA. 2001 Nov 28;286(20):2560-7.PMID: 11722270 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    Interleukin-2 therapy in patients with HIV infection.

    INSIGHT-ESPRIT Study Group; SILCAAT Scientific Committee, Abrams D, Lévy Y, Losso MH, Babiker A, Collins G, Cooper DA, Darbyshire J, Emery S, Fox L, Gordin F, Lane HC, Lundgren JD, Mitsuyasu R, Neaton JD, Phillips A, Routy JP, Tambussi G, Wentworth D.

    N Engl J Med. 2009 Oct 15;361(16):1548-59.PMID: 19828532 [PubMed - indexed for MEDLINE]Related articles

    Supplemental Content

    Find related data